Compare Domino's Pizza, Inc. (DPZ) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Domino's Pizza, Inc. vs Cassava Sciences Inc — how do they compare? Domino's Pizza, Inc. trades at $309.87 (market cap $10.21B), while Cassava Sciences Inc trades at $0.82 (market cap $39.40M). The key difference: Domino's Pizza, Inc. is far larger — about 259.1× Cassava Sciences Inc's market cap, and Domino's Pizza, Inc. pays a 2.58% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Domino's Pizza, Inc. for 106 Days and Cassava Sciences Inc for 37 Days on average.
| DPZ | FLNA | |
|---|---|---|
Market Cap | $10.21B | $39.40M |
Volume | 916,737 | 759,018 |
Sector | Consumer Cyclical | Health |
52-Week High | $438.42 | $4.64 |
52-Week Low | $282.89 | $0.68 |
Typical Hold Time | 106 Days | 37 Days |
Enterprise Value | $15.17B | -$43.28M |
Dividend Yield | 2.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Domino's Pizza (DPZ) trades at $303.10, showing minimal daily movement with a 0.08% gain. The stock faces technical headwinds with bearish moving averages and overbought RSI signals, while recent earnings misses and high debt levels of $5.7 billion create fundamental concerns. However, analyst sentiment remains positive with a $373 consensus price target representing 23% upside potential, supported by consistent revenue growth and strong profitability margins.
The outlook balances strong cash flow generation and market leadership against significant leverage and recent earnings disappointments. Investment opportunity exists in the valuation discount to analyst targets, but risks include debt servicing costs, competitive pressures, and execution challenges in maintaining growth momentum amid economic uncertainty.
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
